ライフサイエンスコーパス: programmed cell death

1 tablished form of developmentally controlled programmed cell death.

2 herbivore recognition, defence signalling or programmed cell death.

3 to either recover ER functionality or ignite programmed cell death.

4 d by a decrease in this inflammatory form of programmed cell death.

5 ers chloroplast and peroxisome autophagy and programmed cell death.

6 kb DNA fragments during the first stages of programmed cell death.

7 ease family that coordinate inflammation and programmed cell death.

8 y inflammasomes that induce inflammation and programmed cell death.

9 ration and avoid terminal differentiation or programmed cell death.

10 key components of inflammatory signaling and programmed cell death.

11 ted to the induction of ROS accumulation and programmed cell death.

12 e mechanism that prevents anoikis, a form of programmed cell death.

13 ich govern the edibility of cells undergoing programmed cell death.

14 rtant functions in seed maturation and plant programmed cell death.

15 daptive immunity; and dormancy induction, or programmed cell death.

16 traditional therapies that rely on apoptotic programmed cell death.

17 elling to a downstream signaling cascade and programmed cell death.

18 a, such as aging, immunity, proteostasis and programmed cell death.

19 ar sphingolipid levels needed for growth and programmed cell death.

20 cortex, where their numbers are adjusted by programmed cell death.

21 ant response, mitochondrial trafficking, and programmed cell death.

22 vity-dependent migration arrest, wiring, and programmed cell-death.

23 e effects of a neutralizing antibody against programmed cell death 1 (PD-1) and an agonist of OX40 (p

24 otoxic T lymphocyte antigen 4 (CTLA-4), anti-programmed cell death 1 (PD-1) and anti-programmed cell

25 izumab, a checkpoint inhibitor targeting the programmed cell death 1 (PD-1) axis, has shown promising

26 hereby CD8+ T cell activation in response to programmed cell death 1 (PD-1) blockade induced a progra

27 ble T cell exhaustion limits the efficacy of programmed cell death 1 (PD-1) blockade.

28 ith shifts in memory phenotype and decreased programmed cell death 1 (PD-1) expression.

29 s subsequently started on nivolumab, an anti-programmed cell death 1 (PD-1) immune checkpoint inhibit

30 Programmed cell death 1 (PD-1) inhibitors have limited e

31 Programmed cell death 1 (PD-1) is critical for T regulat

32 lymphocyte-associated protein 4 (CTLA-4) and programmed cell death 1 (PD-1) partially reverse this ef

33 23 patients who received anti-CTLA-4 or anti-programmed cell death 1 (PD-1) therapy were identified,

34 ion in lymphocyte activation gene 3 (LAG-3), programmed cell death 1 (PD-1), and T cell immunoglobuli

35 lymphocyte-associated protein 4 (CTLA-4) and programmed cell death 1 (PD-1), or CTLA-4 and the PD-1 l

36 l studies that elucidated the biology of the programmed cell death 1 (PD-1), programmed cell death 1

37 Cancer immunotherapies that target the programmed cell death 1 (PD-1):programmed death-ligand 1

38 es cytotoxic T lymphocyte antigen 4 (CTLA4), programmed cell death 1 (PD1) and PD1 ligand 1 (PD-L1) h

39 Furthermore, co-blockade of TIM3 and programmed cell death 1 (PD1) can result in tumour regre

40 ll death 1 ligand 1 (PDL1) with its receptor programmed cell death 1 (PD1) inhibits T cell responses,

41 otoxic T lymphocyte antigen 4 (CTLA4) or the programmed cell death 1 (PD1) pathway have achieved impr

42 umors do not always respond to inhibitors of programmed cell death 1 (PDCD1, also called PD1).

43 s without brain metastasis treated with anti-programmed cell death 1 agents.

44 D-L1) to enrich for patient response to anti-programmed cell death 1 and anti-PD-L1 therapies.

45 d and Drug Administration approval of 2 anti-programmed cell death 1 antibodies (pembrolizumab and ni

46 ir deficiencies and the efficacy of the anti-programmed cell death 1 drugs, have led to US Food and D

47 T-cell exhaustion features including reduced programmed cell death 1 expression and increased T-cell

48 ology of the programmed cell death 1 (PD-1), programmed cell death 1 ligand 1 (PD-L1) and cytotoxic T

49 Tissue expression of programmed cell death 1 ligand 1 (PD-L1) and programmed

50 anti-programmed cell death 1 (PD-1) and anti-programmed cell death 1 ligand 1 (PD-L1) antibodies, are

51 first-line setting, the addition of the anti-programmed cell death 1 ligand 1 (PD-L1) antibody atezol

52 However, the consequences of programmed cell death 1 ligand 1 (PD-L1) ligation in T c

53 atic tumour biopsy for central assessment of programmed cell death 1 ligand 1 (PD-L1) status.

54 on of clinically relevant targets, including programmed cell death 1 ligand 1 (PD-L1), in a STING-dep

55 ression in human HCC correlates with that of programmed cell death 1 ligand 1 (PD-L1), PD-L2, and oth

56 f programmed cell death protein 1 (PD-1) and programmed cell death 1 ligand 1 (PD-L1).

57 The interaction of programmed cell death 1 ligand 1 (PDL1) with its recepto

58 ceptors (programmed cell death protein 1 and programmed cell death 1 ligand 1) were induced.

59 programmed cell death 1 ligand 1 (PD-L1) and programmed cell death 1 ligand 2 (PD-L2) has been shown

60 In this study, we demonstrate that programmed cell death 1 ligand 2 (PD-L2) regulates the p

61 We generated an oligomeric form of programmed cell death 1 ligand chimeric with core strept

62 Blockade of programmed cell death 1 molecules, improved survival of

63 gen-4, and 85 received monotherapy targeting programmed cell death 1 or its ligand.

64 lymphocyte-4 (CTLA-4) agent, and 135 an anti-programmed cell death 1 or ligand 1 (PD-1/L1) agent.

65 The programmed cell death 1 pathway as an important immune c

66 mmed-death ligand 1 (PD-L1) and its receptor programmed cell death 1 promotes T-cell-mediated immunos

67 To determine the efficacy of programmed cell death 1 receptor (PD-1) inhibitors in lo

68 ease of a cell exhaustion marker expression, programmed cell death 1 receptor on T-cell were also obs

69 recently defined a novel population of PD-1 (programmed cell death 1)+ TCF1 (T cell factor 1)+ virus-

70 T cells, such as programmed death-ligand 1, programmed cell death 1, or transforming growth factor b

71 hronic viral infections have defined a novel programmed cell death 1-positive (PD-1(+)) T cell factor

72 red CD20+ B cells, and relatively few PD-1+ (programmed cell death 1-positive) T cells, an immunophen

73 e expression of inhibitory receptors such as programmed cell-death 1 (PD-1)(5-8).

74 Chronic inflammation is promoted by non-programmed cell death(1,2); however, how inflammation is

75 mphocyte-associated antigen 4 (a-CTLA-4) and programmed cell death-1 (a-PD-1) was largely unsuccessfu

76 given before checkpoint inhibition with anti-programmed cell death-1 (anti-PD-1) antibodies inhibited

77 erging immune therapy, such as with the anti-programmed cell death-1 (anti-PD-1) monoclonal antibody

78 ssfully used for sensitive quantification of programmed cell death-1 (PD-1) and programmed cell death

79 phenotypic changes induced by treatment with programmed cell death-1 (PD-1) blockade in a genetically

80 lling rates of durable clinical responses to programmed cell death-1 (PD-1) blockade, advances are ne

81 Because cHL is uniquely vulnerable to programmed cell death-1 (PD-1) blockade, PD-1 blockade g

82 variety of cancers using immunotherapy with programmed cell death-1 (PD-1) checkpoint blockade.

83 exhaustion mediated in part by expression of programmed cell death-1 (PD-1) encoded by the Pdcd1 gene

84 renders tumors immunogenic and sensitive to programmed cell death-1 (PD-1) immune checkpoint inhibit

85 Ligation of programmed cell death-1 (PD-1) in the tumor microenviron

86 Programmed cell death-1 (PD-1) is an inhibitory receptor

87 ic aberrations at 9p24 and overexpression of programmed cell death-1 (PD-1) ligands (PD-L1), it is hy

88 rs the tumor microenvironment and suppresses Programmed cell death-1 (PD-1) protein, an immune checkp

89 Programmed cell death-1 (PD-1), an antigen co-receptor o

90 l immunoglobulin and mucin-3 (TIM-3), and/or programmed cell death-1 (PD-1), and acquire an anergic p

91 idney retransplantation performed after anti-programmed cell death-1 (PD-1)-related allograft rejecti

92 Programmed cell death-1 (PD-1)-targeted therapies enhanc

93 ytotoxic T lymphocyte antigen-4 (CTLA-4) and programmed cell death-1 (PD-1).

94 Programmed cell death-1 (PD-1)/programmed death ligand-1

95 ccompanied by the persistent upregulation of programmed cell death-1 and absent memory cell formation

96 -small-cell lung cancer (NSCLC) treated with programmed cell death-1 axis inhibition.

97 esulted in MC38 tumor clearance and improved programmed cell death-1 checkpoint blockade responses to

98 ) is compartmentalized into "niches" rich in programmed cell death-1 ligand (PD-L1)-positive HRS cell

99 hilic polymer layers attached to anti-PD-L1 (programmed cell death-1 ligand-1) antibody for molecular

100 Programmed cell death-1 mRNA expression was increased in

101 Clinical trials of programmed cell death-1 pathway inhibitors for advanced

102 ample, we found that tonic signalling by the programmed cell death-1 receptor (PD-1) results in resid

103 patients with aMCC receiving first-line anti-programmed cell death-1 therapy.

104 fluence the response of tumors to anti-PD-1 (programmed cell death-1) immunotherapy in preclinical mo

105 valuated for inhibitory activity against the programmed cell death-1/programmed death-ligand 1(PD-1/P

106 The anti-Programmed cells Death-1 was stopped and a topical corti

107 Programmed cell death 4 (PDCD4) is a proinflammatory tum

108 WDR77 physically interacted with programmed cell death 4 (PDCD4) that suppresses translat

109 gation of peroxisomes during final stages of programmed cell death and can be used as a marker of thi

110 Programmed cell death and early activity contribute to t

111 essential in the initiation and execution of programmed cell death and inflammation processes.

112 ed cysteine proteases that play key roles in programmed cell death and inflammation.

113 CRISPR-Cas and DNA repair systems as well as programmed cell death and signal transduction mechanisms

114 ed in Arabidopsis as a positive regulator of programmed cell death and we report here on its role in

115 n eukaryotes with a key role in homeostasis, programmed cell death, and aging.

116 and ephrin A1, which regulate proliferation, programmed cell death, and neuronal migration, respectiv

117 s (NF-kappaB) signaling, cell proliferation, programmed cell death, and survival and is crucially inv

118 rtic proteases involved in the regulation of programmed cell death (apoptosis) and a number of other

119 ity, causing cellular stress, and increasing programmed cell death (apoptosis) in the tissues require

120 species from cells or to selectively induce programmed cell death (apoptosis) or uncontrolled cell d

121 d play a central role in the early stages of programmed cell death (apoptosis).

122 The 2 major modes of programmed cell death, apoptosis and necroptosis, share

123 chemotherapy rely on cancer cells bypassing programmed cell death by apoptosis.

124 hrough a recently described distinct form of programmed cell death called NETosis.

125 Furthermore, programmed cell death can also represent a defense mecha

126 the binding of Annexin V, demonstrates that programmed cell death can be promoted by the peptide ass

127 Although programmed cell death can control intracellular bacteria

128 Programmed cell death contributes to host defense agains

129 Necroptosis is a form of programmed cell death defined by activation of the kinas

130 Pyroptosis is an inflammatory form of programmed cell death following cellular damage or infec

131 ial markers, we found that the regulation of programmed cell death (GO: 0043067; GO: 0043069), regula

132 developmental program that normally leads to programmed cell death, H. avenae may permit xylem vessel

133 (ECM) is required to combat the induction of programmed cell death in a variety of distinct cell type

134 ) family, which are emerging as mediators of programmed cell death in a variety of processes that reg

135 Plant metacaspases mediate programmed cell death in development, biotic and abiotic

136 icum) Cipk6 regulates immune and susceptible Programmed cell death in immunity transforming Ca(2+) si

137 victims, which can be seen as an analogy of programmed cell death in multicellular organisms.

138 s', and provide insights into the control of programmed cell death in plants.

139 solenopsins induced a type of autophagic and programmed cell death in T. cruzi.

140 A. fumigatus infection induced inflammatory programmed cell death in the form of pyroptosis, apoptos

141 infected erythrocytes in culture by inducing programmed cell death in the parasites, and that vaccina

142 s in the nuclear architecture, and activated programmed cell death, in D. citri midgut cells.

143 cross talk of caspases in the regulation of programmed cell death, inflammation, and innate immune r

144 plicated its role in signaling to SI-induced programmed cell death involving a DEVDase.

145 Its role in inducing programmed cell death is closely associated with the for

146 Apoptosis or programmed cell death is closely regulated by pro- and a

147 Apoptosis, a process of programmed cell death, is assumed to be the main mechani

148 Ferroptosis, a non-apoptotic form of programmed cell death, is triggered by oxidative stress

149 o quantify the uptake of (18)F-BMS-986192, a programmed cell death ligand 1 (PD-L1) adnectin PET trac

150 IHC staining for programmed cell death ligand 1 (PD-L1) and mismatch repa

151 tibody) in advanced solid tumours expressing programmed cell death ligand 1 (PD-L1) and report here o

152 Here, we show that in vitro blockade of programmed cell death ligand 1 (PD-L1) by an anti-PD-L1

153 d neck squamous cell carcinoma (HNSCC), with programmed cell death ligand 1 (PD-L1) expression associ

154 Programmed cell death ligand 1 (PD-L1) is part of an imm

155 xpression of the commonly assessed biomarker programmed cell death ligand 1 (PD-L1) nor tumor mutatio

156 melanoma cells upregulate the expression of programmed cell death ligand 1 (PD-L1) on mouse immature

157 tion was by clinical breast cancer stage and programmed cell death ligand 1 (PD-L1) status.

158 US Food and Drug Administration (FDA) detect programmed cell death ligand 1 (PD-L1) to enrich for pat

159 (18)F-BMS-986192, an adnectin-based human programmed cell death ligand 1 (PD-L1) tracer, was devel

160 ed 'don't eat me' signals-including CD47(1), programmed cell death ligand 1 (PD-L1)(2) and the beta-2

161 luding indoleamine 2,3-dioxygenase (IDO) and programmed cell death ligand 1 (PD-L1), and resulted in

162 enhanced levels of the coinhibitory molecule programmed cell death ligand 1 (PD-L1), the ligand for P

163 ts of IFN-gamma and sensitize tumors to PD-1/programmed cell death ligand 1 blockade-induced rejectio

164 nt programmed cell death protein 1 (PD-1) or programmed cell death ligand 1 can enhance effector T-ce

165 receptor 1, STAT3 mRNA increase, as well as programmed cell death ligand 1 expression, accompanied b

166 fects and FN3-PARs reduced immunosuppressive programmed cell death ligand-1 (PD-L1) expression by dow

167 on of IL10, as well as the expression of the programmed cell death ligand-1 (PD-L1/CD274), was recent

168 cation of programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) in 15 representat

169 ed trials on programmed cell death protein-1/programmed cell death-ligand 1 pathway inhibition are ne

170 valuation of programmed cell death protein-1/programmed cell death-ligand 1 pathway inhibition in sep

171 ltrating lymphocytes, cyclin E, adipophilin, programmed cell death-ligand 1, and elastase staining an

172 is structural change results in induction of programmed cell death like physiological hallmarks, whic

173 ith the cell cycle of Leishmania, inducing a programmed cell death-like mechanism and affecting DNA r

174 cells undergoing apoptosis, suggesting that programmed cell death may limit viral dissemination in t

175 s in Nicotiana benthamiana led to a delay in programmed cell death normally associated with AvrPto re

176 Programmed cell death occurs in a highly reproducible ma

177 could enter cells, inhibit growth and induce programmed cell death, opening new opportunities for the

178 Programmed cell death or apoptosis is a central biologic

179 epidermal patterning, vascular development, programmed cell death, organ abscission, senescence, and

180 cA(4) signal, providing an off ramp from the programmed cell death pathway in cells that successfully

181 f the inflammatory cytokine IL-1beta and the programmed cell death pathway pyroptosis in a caspase-1-

182 aled that nucleic acid sensors also activate programmed cell death pathways as an innate immune respo

183 n, and vRNP sensing to trigger activation of programmed cell death pathways during IAV infection.

184 te that caspase-6 promotes the activation of programmed cell death pathways including pyroptosis, apo

185 This study reveals the effect of antiviral programmed cell death pathways on inflammation, shows th

186 m that may save cellular energy and activate programmed cell death pathways, in the absence of glucos

187 luenza virus infection induces activation of programmed cell death pathways.

188 ells in a manner that does not involve known programmed cell death pathways.

189 depletion and/or activation of PAR-dependent programmed cell death pathways.

190 suppressed by extracellular matrix (ECM) and programmed cell death (PCD) along the embryonic midline.

191 Programmed cell death (PCD) in filamentous fungi prevent

192 complementary light chain VL domain, caused programmed cell death (PCD) in mutant RAS expressing cel

193 enes whose orthologs have been implicated in programmed cell death (PCD) in other species.

194 reactive oxygen species (ROS) production and programmed cell death (PCD) in tapetal cells, resulting

195 te pollen and pistil S-determinants triggers programmed cell death (PCD) of incompatible pollen.

196 S triggers pollen tube growth inhibition and programmed cell death (PCD) of self-pollen.

197 d in cell-signalling, stress acclimation and programmed cell death (PCD) pathways in plants, fungi, p

198 Pyroptosis, a unique form of programmed cell death (PCD) that is characterized by DNA

199 nthesis is a signal molecule that can induce programmed cell death (PCD) through the action of the OX

200 osis during the critical postnatal period of programmed cell death (PCD).

201 immune modulator because of its role in the programmed cell death PD-L1/PD-1 pathway.

202 that most hypertrophic chondrocytes undergo programmed cell death prior to bone formation.

203 This programmed cell death process is mediated by several sig

204 our study reveals a novel activity-dependent programmed cell death process required for the removal o

205 died the involvement of necroptosis (another programmed cell death process) and inflammation in alkyl

206 ere found to control nonself recognition and programmed cell death processes.

207 ediated by the activation of the necroptotic programmed cell-death program by a cell-autonomous mecha

208 Programmed cell death promotes homeostatic cell turnover

209 Blocking programmed cell death protein (PD)-1 signaling, which me

210 The combination of IRE and anti-programmed cell death protein 1 (anti-PD1) immune checkp

211 vaccinated patients newly treated with anti-programmed cell death protein 1 (PD-1) agents (nivolumab

212 ften express the immune checkpoint receptors programmed cell death protein 1 (PD-1) and cytotoxic T l

213 une checkpoints, such as the one mediated by programmed cell death protein 1 (PD-1) and its ligand PD

214 Immunotherapies that target programmed cell death protein 1 (PD-1) and its ligand PD

215 of peptide inhibitors using a case study of programmed cell death protein 1 (PD-1) and programmed ce

216 The programmed cell death protein 1 (PD-1) and programmed de

217 ibitory checkpoint receptors (ICRs), such as programmed cell death protein 1 (PD-1) and T cell immuno

218 Signaling between programmed cell death protein 1 (PD-1) and the PD-1 liga

219 Furthermore, programmed cell death protein 1 (PD-1) antibody (aPD-1)

220 with declining CAR T cells, rhesusized anti-programmed cell death protein 1 (PD-1) antibody was admi

221 andomized to receive adjuvant, post-surgical programmed cell death protein 1 (PD-1) blockade alone.

222 Herein, we evaluated the efficacy of programmed cell death protein 1 (PD-1) blockade in a mur

223 The efficacy of programmed cell death protein 1 (PD-1) blockade in metas

224 Response to programmed cell death protein 1 (PD-1) blockade is often

225 as performed to assess CD8, FOXP3, CD56, and programmed cell death protein 1 (PD-1) expression on str

226 Programmed cell death protein 1 (PD-1) has become one of

227 and anti-tumour activity of pembrolizumab, a programmed cell death protein 1 (PD-1) inhibitor, added

228 Programmed cell death protein 1 (PD-1) is a critical inh

229 Programmed cell death protein 1 (PD-1) is a negative reg

230 Programmed cell death protein 1 (PD-1) is an inhibitory

231 Programmed cell death protein 1 (PD-1) ligation delimits

232 red for expression of the checkpoint protein programmed cell death protein 1 (PD-1) on cytotoxic T ly

233 Blockade of immune-checkpoint programmed cell death protein 1 (PD-1) or programmed cel

234 s immune function through its binding of the programmed cell death protein 1 (PD-1) receptor.

235 of monocytes with T cells, nor did it induce programmed cell death protein 1 (PD-1) signaling that ca

236 lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) to suppress antit

237 den (TMB), microsatellite instability (MSI), programmed cell death protein 1 (PD-1), and its ligand (

238 ne checkpoint inhibitors (ICI) targeting the programmed cell death protein 1 (PD-1), or its ligand PD

239 Programmed cell death protein 1 (PD-1)-immune checkpoint

240 kappaB (NF-kappaB), JAK/STAT signaling, and programmed cell death protein 1 (PD-1)-mediated immune e

241 Understanding resistance to antibody to programmed cell death protein 1 (PD-1; anti-PD-1) is cru

242 The engagement of programmed cell death protein 1 (PD-1; encoded by the PD

243 Removal of a third gene encoding programmed cell death protein 1 (PD-1; PDCD1), was perfo

244 ype most susceptible to antibodies targeting programmed cell death protein 1 (PD1) and is characteriz

245 (Th17) phenotype with lower ICOS and higher programmed cell death protein 1 (PD1) expression.

246 treated with nivolumab, an antibody against programmed cell death protein 1 (PD1).

247 Rgammat(+) T cells expressing a low level of programmed cell death protein 1 and a high level of OX40

248 n 7 receptor), whereas inhibitory receptors (programmed cell death protein 1 and programmed cell deat

249 from serial tumor biopsies before and after programmed cell death protein 1 blockade identifies chro

250 nd mapping out programmed-death ligand 1 and programmed cell death protein 1 in tumors with cellular

251 .01), whereas all other imaging criteria and programmed cell death protein 1 ligand expression did no

252 Programmed cell death protein 1 ligand expression status

253 dictive value for response evaluation during programmed cell death protein 1 or PD-L1 immune checkpoi

254 l activation of both the T-cell receptor and programmed cell death protein 1 pathways positively corr

255 Programmed cell death protein 1 receptor (PD-1) is a cel

256 cited additive antitumor responses with anti-programmed cell death protein 1 therapy.

257 Finally, the combination of anti-programmed cell death protein 1 with CCR2i considerably

258 se models, immune checkpoints, such as PD-1 (programmed cell death protein 1), control the threshold

259 type and function characterized by increased programmed cell death protein 1, CXCR3, and IFN-gamma ex

260 Programmed cell death protein 1:programmed death ligand

261 higher stability and stronger inhibition on programmed cell death protein 4 (PDCD4) translation, res

262 n recent years, it has been established that programmed cell death protein ligand 1 (PD-L1)-mediated

263 est potential to inhibit immune checkpoints: programmed cell death protein-1 (PD-1) (-6.8 kcal/mol) a

264 Four patients received anti-programmed cell death protein-1 (PD-1) antibody and 2 re

265 lymphocyte-associated protein-4 (CTLA-4) and programmed cell death protein-1 (PD-1) have been hailed

266 As the programmed cell death protein-1 (PD-1) inhibitory axis r

267 Aberrant expression of T cell-resident programmed cell death protein-1 (PD-1) is known to promo

268 t interfere with the binding of the receptor programmed cell death protein-1 (PD-1) to programmed dea

269 xpression of inhibitory receptors, including programmed cell death protein-1 (PD-1), is associated wi

270 L-tyrosine (FSY) was incorporated into human programmed cell death protein-1 (PD-1).

271 s in beta2m knockout mice mainly comprised a programmed cell death protein-1 receptor (PD-1(+)) subse

272 In this first clinical evaluation of programmed cell death protein-1/programmed cell death-li

273 Further randomized trials on programmed cell death protein-1/programmed cell death-li

274 Targeted blockade of programmed-cell-death-protein-1 (PD-1)-an immune checkpo

275 Innate immune-mediated programmed cell death (pyroptosis, apoptosis, necroptosi

276 cell adherence, and postfusion by triggering programmed cell death reactions.

277 afety and efficacy of pembrolizumab (an anti-programmed cell death receptor 1 [PD-1] antibody) in adv

278 th was paralleled by an up-regulation of the programmed cell death receptor 1 on CD8(+) and CD4(+) T

279 tal case of encephalitis arising during anti-programmed cell death receptor 1 therapy in a patient wi

280 ety and potential benefit of nivolumab (anti-programmed cell death receptor 1) monotherapy beyond Res

281 rivascular regions in close association with programmed cell death receptor 1-positive infiltrating l

282 that T cells transmit pN forces through the programmed cell death receptor-1 (PD1), a major target i

283 Evasion of programmed cell death represents a critical form of onco

284 Apoptosis, a conserved form of programmed cell death, shows interspecies differences th

285 ptosis, a fundamental homeostatic process of programmed cell death that is highly conserved across ev

286 Ferroptosis is a form of programmed cell death that is pathogenic to several acut

287 review will focus on the mechanisms of host programmed cell death that occur during opportunistic fu

288 Necroptosis is a highly inflammatory form of programmed cell death that results from MLKL-mediated di

289 mammary cell death was via lysosome-mediated programmed cell death through upregulation of cathepsin

290 nhibitor 1 (BI1) modulates ER stress-induced programmed cell death through yet-unknown mechanisms.

291 Interestingly, recent evidence suggests that programmed cell death triggered by nucleic acid sensors

292 ents are considered to induce apoptosis-like programmed cell death via hyperproduction of reactive ox

293 evels, increases DSBs, and may contribute to programmed cell death via nuclear loss-of-function.

294 ealed that genes associated with defense and programmed cell death were strongly activated, including

295 tical granule exocytosis, in developmentally programmed cell death when the predominant pro-apoptotic

296 ctor-triggered immunity (ETI) often leads to programmed cell death, which is restricted by NPR1, an a

297 Programmed cell death widely but heterogeneously affects

298 'ferroptosis', a recently discovered form of programmed cell death with promising therapeutic targets

299 mechanisms governing caspase activation and programmed cell death with special emphasis on the recen

300 We also show that cell swelling induces programmed cell death within 3 h in a MSL10-dependent ma